Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05134779 · ClinicalTrials.gov registry record
De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You
A clinical trial of Breast Cancer, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- 400
- Enrollment target
- 2
- Study locations
NCT05134779 is a study of Breast Cancer that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 400 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05134779, a study of Breast Cancer, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a live biobank study for breast cancer (BC) patients where samples will be collected at inflection points in the course of the disease.
Conditions Studied
Interventions
- PROCEDURE Live Biobank
Study Locations (2)
New York
- Brooklyn Methodist Hospital - NewYork Presbyterian - New York
- New York Presbyterian Hospital - Queens - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2022-01-12 |
| Est. Completion | 2028-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05134779
The ClinicalTrials.gov registry entry for NCT05134779 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Live Biobank is the first listed.
NCT05134779 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05134779 about?
NCT05134779 is a clinical study titled "De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You". This is a live biobank study for breast cancer (BC) patients where samples will be collected at inflection points in the course of the disease.
What is the current status of trial NCT05134779?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2022-01-12. Estimated completion is 2028-12-31.
What conditions does trial NCT05134779 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05134779?
The interventions under investigation include: Live Biobank (PROCEDURE).
Who is sponsoring clinical trial NCT05134779?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05134779 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.